Study at a glance
Researchers report that an experimental gene-therapy vector preserved measures of retinal structure and function for as long as 15 months in a mouse model of PDE6B-related retinitis pigmentosa (RP). The work, published in Nature's Eye journal, tested the approach in rd10 mice; it was not a study in people.
The treatment used an adeno-associated virus type 8 (AAV8) vector to deliver a human PDE6B gene. The vector was designed with a rhodopsin-kinase (RK/GRK1) promoter, intended to direct gene activity in photoreceptors, and included the PDE6B gene's 3′ untranslated region (3′UTR), a regulatory sequence that can influence gene expression.
Why PDE6B is relevant to RP
RP is a group of inherited retinal diseases in which rod photoreceptors progressively degenerate and cone photoreceptors can later be affected. The publisher notes that disease-causing changes in genes for components of the PDE6 complex account for an estimated 4% to 5% of RP cases, with many involving PDE6B, which encodes the beta subunit of the complex.
The rd10 mouse used in this research has two altered copies of its mouse Pde6b gene. This causes retinal degeneration after the first two weeks of life, making the model useful for evaluating potential treatments for PDE6B deficiency. However, findings in this model do not establish that a treatment will have similar effects in people with PDE6B-related RP.
What the researchers tested
The investigators gave rd10 mice a subretinal injection of the experimental AAV8-RK-PDE6B-3′UTR vector at postnatal day 12. Subretinal delivery places treatment into the space beneath the retina.
According to the paper, treated mice had sustained preservation on several study measures over follow-up lasting up to 15 months. These included:
- visual-acuity testing;
- electroretinography (ERG), which measures electrical responses of the retina to light;
- optical coherence tomography (OCT), an imaging method used to assess retinal layers; and
- immunohistochemistry, a laboratory technique used to examine cells and proteins in tissue.
The authors describe this as the longest reported follow-up of retinal function and structure for AAV-mediated PDE6B gene supplementation in the rd10 model.
The study also compared constructs with and without the PDE6B 3′UTR. In laboratory cell testing, adding this sequence increased PDE6B expression. In mice assessed four weeks after treatment, the 3′UTR-containing construct showed better functional rescue than the comparison construct, according to the researchers.
What this development may mean—and its limits
This study provides preclinical evidence that a vector design combining a standard AAV8 capsid, a photoreceptor-directed promoter, and a PDE6B regulatory sequence can produce durable retinal findings in this particular mouse model. The inclusion of the 3′UTR is notable because it was specifically evaluated as a possible way to improve expression of the delivered gene.
Important limitations remain. The publisher text describes animal and laboratory experiments, not a clinical trial, and it does not provide human safety, dosing, durability, or effectiveness data. The treatment was delivered very early in the mice's lives, and the reported results cannot determine which people with PDE6B-related RP, if any, could be eligible for or benefit from a future therapy. The supplied material also does not indicate that this specific construct has entered human testing.
Publisher source
Nature, published November 2, 2026: AAV8-PDE6B with 3′UTR provides rescue of photoreceptor structure and function in the rd10 mouse model of retinitis pigmentosa